Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Twelve states have an adult obesity prevalence of 35% or more.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
Obesity increased the risk of liver disease to a smaller extent, according to a meta-analysis study.
While women have a lower risk for NAFLD, once present, the disease advanced more rapidly.
This connection may be attributable to lower iron levels.
A new study analyzed how non-alcoholic fatty liver disease affects maternal health outcomes.
Non-alcoholic fatty liver disease can be driven by toxin exposure.
Instead of non-alcoholic fatty liver disease, they suggest calling it metabolic-associated fatty liver disease.
Researchers believe this finding may have implications for human health.
New research is emerging about how the respiratory virus spreads and how people can protect themselves and others.
Liver scarring was associated with poorer health outcomes and a higher risk of death for people with non-alcoholic fatty liver disease.
Women have a lower risk of heart disease than men, but this protective effect is diminished in those with fatty liver disease.
A new study suggested that a compound found in veggies such as broccoli, kale and Brussels sprouts may help maintain liver health.
Those with fatty liver disease and cirrhosis should undergo regular screening.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.